Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Chronic Myeloproliferative Neoplasms

Impact of interferon on a triple positive polycythemia vera

Leukemia volume 34, pages 1210–1212 (2020)Cite this article

Subjects

Sir,

We read the paper by Julia Czech et al., “JAK2V617F but not CALR mutations confer increased molecular responses to interferon- via JAK1/STAT1 activation” [1], with great interest. This paper reports that JAK2V617F-mutated patients with myeloproliferative neoplasms (MPN) have a better molecular response to pegylated interferon-α (IFN) treatment than patients with mutated CALR. However, the authors noted similar hematological responses in groups of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF). Here, we report on an unusual polycythemia vera (PV) patient who harbored initially only a JAK2V617F mutation, but secondary also a CALR del52 and a MPLS505N mutations. The CALR del52 clone was resistant to IFN, which led to the absence of complete hematological (CHR) and complete molecular responses (CMR).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia. 2019;33:995–1010.

  2. Kiladjian J-J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72.

    Article  CAS  Google Scholar 

  3. Ianotto J-C, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, et al. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018;103:438–46.

    Article  CAS  Google Scholar 

  4. Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37:1041–5.

    Article  CAS  Google Scholar 

  5. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFN -2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762–9.

    Article  CAS  Google Scholar 

  6. Broséus J, Park J-H, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood. 2014;124:3964–6.

    Article  Google Scholar 

  7. Usseglio F, Beaufils N, Calleja A, Raynaud S, Gabert J. Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F essential Thrombocythemia. J Mol Diagn. 2017;19:92–8.

    Article  CAS  Google Scholar 

  8. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med. 2013;369:2379–90.

    Article  CAS  Google Scholar 

  9. Mansier O, Paz DL, Ianotto J-C, Bris YL, Chauveau A, Boyer F, et al. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol. 2018;93:E84–6.

    Article  Google Scholar 

  10. Nussenzveig RH, Pham HT, Perkins SL, Prchal JT, Agarwal AM, Salama ME. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2V617F allelic burden. Leuk Lymphoma. 2016;57:1429–35.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the ANR - 15-CE17-0021-03 (GenRed), the ANR-11-LABX-0051 (labex GR-Ex) and the association “Chalon sur Saône-Tulipes contre le cancer”. IP was founded by MPN research foundation and INCA PLbio 2018.

Author information

Authors and Affiliations

  1. Service d’Hématologie Biologique, Pôle Biologie, CHU de Dijon, Dijon, France

    Hugo Campario, Valentin Bourgeois, Pauline Martin, Antoine Brustel, Mathilde Filser & François Girodon

  2. Inserm U1231, Université de Bourgogne, Dijon, France

    Hugo Campario & François Girodon

  3. Gustave Roussy, INSERM, UMR 1170, Laboratoire d’Excellence GR-Ex, Villejuif, France

    Matthieu Mosca & Isabelle Plo

  4. Gustave Roussy, Université Paris-Sud, UMR, 1170, Villejuif, France

    Matthieu Mosca & Isabelle Plo

  5. Laboratoire d’Excellence GR-Ex, Paris, France

    Matthieu Mosca, Isabelle Plo & François Girodon

  6. Laboratoire de génétique chromosomique et moléculaire, Pôle Biologie, CHU de Dijon, Dijon, France

    Bernard Aral

  7. Laboratoire Hématologie-Immunologie, Département Biologie et Pathologie Médicales, Gustave Roussy, France

    Christophe Marzac

Authors
  1. Hugo Campario
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthieu Mosca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard Aral
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valentin Bourgeois
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pauline Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antoine Brustel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mathilde Filser
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christophe Marzac
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Isabelle Plo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. François Girodon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Girodon.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Isabelle Plo, François Girodon: On behalf of the French Intergroup of MPNs (FIM)

François Girodon: On behalf of MPN&MPNr-EuroNet (COST Action BM0902).Ś

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Campario, H., Mosca, M., Aral, B. et al. Impact of interferon on a triple positive polycythemia vera. Leukemia 34, 1210–1212 (2020). https://doi.org/10.1038/s41375-019-0636-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0636-0

This article is cited by

Search

Advanced search

Quick links